Introduction
============

Breast cancer is one of the most common cancers that threaten women's lives around the world, with approximately a 3% chance that a woman will die of breast cancer.[@b1-ott-10-1207] Dynamic interplay between tumors and the immune system is essential for tumor survival, growth, and metastasis.[@b2-ott-10-1207] Development of an invasive cancer is the result of genetic and epigenetic changes within the host. Studies provide clear evidence that genetic variants could be implicated in increasing breast cancer risk.[@b3-ott-10-1207],[@b4-ott-10-1207] The immune system is known to play a major role in preventing tumor progression by recognizing tumor antigens, and dysregulation of immune system activity could contribute to tumorigenesis.[@b5-ott-10-1207] A dynamic association between immune response and breast cancer is important for its progression and incidence.[@b6-ott-10-1207]--[@b8-ott-10-1207] Recent studies have shown that dysregulation of innate immunity receptors such as Toll-like receptors (TLRs) can promote cancer progression.[@b9-ott-10-1207]--[@b12-ott-10-1207] To date, ten functional TLRs have been identified in humans as playing an active role in innate immunity through inflammatory cytokines such as interleukin (IL)-1 and IL-8. TLRs are also expressed in many cancer cells and are known to play a major role in tumor progression through regulating cell proliferation and survival.[@b13-ott-10-1207],[@b14-ott-10-1207] Of this TLR family, TLR-4 is a major TLR that plays an important role in regulating inflammation and immune responses through activating nuclear factor kappa-light-chain enhancer of activated B cells.[@b15-ott-10-1207] This Toll protein is a key receptor for lipopolysaccharide (LPS) from Gram-negative bacteria and is crucial for upregulation of mechanisms of defense against bacterial infections. Several other pathogen-associated molecular patterns, including fusion protein from respiratory syncytial virus and envelope protein from mouse mammary tumor virus, can also stimulate TLR-4 signaling.[@b16-ott-10-1207],[@b17-ott-10-1207] In addition to activating the MyD88-dependent pathway, TLR-4 is the only TLR that can activate the MyD88-independent pathway via its TLR domain-containing adaptor.[@b18-ott-10-1207] TLR-4 has received special attention in cancer research due to its role in tumor progression. It has been previously shown that TLR-4 is expressed in many cancer cells such as human melanoma cells,[@b19-ott-10-1207] human gastric cancer cells,[@b20-ott-10-1207] and human head and neck squamous cell carcinoma.[@b21-ott-10-1207] In addition, TLR-4 has also been linked to breast cancer. Previous studies have demonstrated that TLR-4 depletion leads to increased tumor progression and metastasis in a murine model of breast cancer.[@b9-ott-10-1207] There is evidence that genetic single-nucleotide polymorphisms (SNPs) may cause the impairment of immune responses, and consequently, the development of infectious diseases. The association between the development of infections and chronic inflammation could increase cancer risk. Few associations were observed between TLR genes and risk of developing breast cancer. Several studies highlighted the implication of TLR polymorphisms in pathogenesis of tumors. It was demonstrated that polymorphisms in TLR-2 and TLR-4 were associated with gastric cancer.[@b22-ott-10-1207],[@b23-ott-10-1207] Increasing bodies of evidence have suggested that TLR polymorphism is closely related to inflammation and may increase the risk of developing gastric malignancy.[@b22-ott-10-1207],[@b24-ott-10-1207],[@b25-ott-10-1207] TLR-4 polymorphism was also connected with colon cancer[@b26-ott-10-1207] and hepatitis C virus-induced hepatocellular carcinoma.[@b27-ott-10-1207] In addition, a polymorphism in TLR-10, TLR-6, TLR-2, and TLR-1 was shown to be associated with increasing susceptibility of prostate cancer.[@b28-ott-10-1207],[@b29-ott-10-1207] Other studies have also presented the correlation between TLR-2 polymorphism and papillary thyroid cancer in the Korean population.[@b30-ott-10-1207] Recently, several studies have demonstrated that the presence of the TLR-4 Asp299Gly polymorphism is associated with a higher frequency of prostate cancer in the North Indian population.[@b31-ott-10-1207] It has also been shown that TLRs are implicated in the progression of polyps to tumors and that increased metastatic potential of colorectal cancers was correlated with reduced TLR expression.[@b31-ott-10-1207],[@b32-ott-10-1207] TLR-4 polymorphism rs11536898 has also been shown to be connected with colon cancer.[@b26-ott-10-1207] The TLR-4 Asp299Gly polymorphism and TLR-2 Thr399Ile polymorphism were also observed to be associated with an increased risk of breast cancer.[@b33-ott-10-1207],[@b34-ott-10-1207] In addition, TLR-1 and TLR-6 polymorphisms have been linked with increased susceptibility of breast cancer in the African-American population.[@b35-ott-10-1207],[@b36-ott-10-1207] The present study aims to elucidate the potential correlation of the TLR-4 SNP (*rs2770150*, *rs10759931*, *rs10759932*, and *rs4986790*) with the risk of breast cancer in the Saudi Arabian population.

Materials and methods
=====================

Sample collection
-----------------

Blood samples were collected from 127 subjects with histologically confirmed breast cancer, recruited among patients from King Faisal Medical City (KFMC) in Riyadh, Kingdom of Saudi Arabia (KSA). A detailed description of the breast cancer population is shown in [Table 1](#t1-ott-10-1207){ref-type="table"}. All subjects provided written informed consent to participate in the study and to approve the use of their biological samples for genetic analyses. The design of the study was approved by the local Ethics Committee (number 15-089E) from KFMC, Riyadh. Study subjects provided information on their lifestyle habits, diabetes, and family/personal history of cancer via a structured questionnaire in accordance with the guidelines of the Ethics Committee at KFMC in Riyadh, KSA, to determine demographic characteristics and potential risk factors for breast cancer development. The immunohistochemical (IHC) assay was performed on the fresh tissue samples. The genomic DNA was extracted from blood samples for genotyping.

IHC array
---------

IHC was performed on 3- to 5-mm thick sections obtained from formalin-fixed tissue embedded in paraffin. Histopathological representative tumor areas were defined on hematoxylin/eosin-stained sections. The array blocks were obtained as described elsewhere.[@b37-ott-10-1207] About 5-μm sections from each tumor tissue block were consecutively cut with a microtome (Leica Microsystems GmbH, Wetzlar, Germany). Once the slides were ready, they were incubated for 15--20 minutes in a hot air oven at 60°C. Anti-TLR-4 antibody (H-80, sc-10741; Santa Cruz Biotechnology, CA, USA) was used at 1/100 dilution. Different steps and analyses of IHC were then performed as previously described by Semlali et al.[@b38-ott-10-1207]

DNA extraction
--------------

Three hundred microliters of whole blood was used to extract genomic DNA by using DNA Blood Mini Kit (Qiagen, Qilden, Germany) according to the manufacturer's instructions. After equilibration of blood at room temperature with protease, the blood samples were incubated at 56°C for 10 minutes. Appropriate volume of absolute ethanol was added, and the mixture was spun through the column. The column membrane was washed, and the DNA was eluted with 100 μL elution buffer. The concentration and the purity of DNA were determined by Nano-Drop 800 spectrophotometer (Thermo Fisher Scientific).

Genotyping
----------

TLR-4 SNPs (rs2770150, rs10759931, rs10759932, and rs4986790) were assessed using TaqMan assay as previously described.[@b39-ott-10-1207] The positional information of the SNPs is described in [Table S1](#SD1-ott-10-1207){ref-type="supplementary-material"}. For this purpose, about 10 ng of DNA from each sample was used per reaction with 5.6 μL of 2X Universal Master Mix and 200 nM primers. All genotypes were determined by using an ABI 7500 real-time PCR machine.

Statistical analysis
--------------------

As described previously by Semlali et al,[@b38-ott-10-1207] genotype and allelic frequencies were compared using Fisher's exact test (two-tailed) to calculate the *χ*^2^ value with Yates corrections, and allelic odds ratios (ORs) with 95% confidence intervals (CIs). Statistical analysis was performed using SPSS (Statistical Package for the Social Sciences) 16.0 software for Windows.

Results
=======

Analysis of clinical data parameters
------------------------------------

A total of 127 breast cancer cases and 117 healthy controls were enrolled in the study. The clinical characteristics of the patients, including age, nationality, estrogen receptor (ER) status, family history, and stage of breast cancer, were recorded and compared to the control patients. The study population was divided into two age groups: under 48 years and over 48 years ([Table 1](#t1-ott-10-1207){ref-type="table"}).

Evaluation of expression of TLR-4 protein in breast cancer tissues
------------------------------------------------------------------

TLR-4 has been reported as an indicator of various types of cancers. In the present study, we investigated whether the expression of TLR-4 in breast cancer has any prognostic value in the Saudi population and whether TLR-4 expression is related to the TLR-4 polymorphism specially located in the regulatory regions (promoter and 5′ upstream). The expression of TLR-4 protein in breast cancer and normal tissues was determined in a large cohort of 70 clinical breast samples in a tissue micro-array format by IHC. As shown in [Figure 1](#f1-ott-10-1207){ref-type="fig"}, the levels of TLR-4 protein were very low in normal breast tissues. The strength of positive staining gradually increased from ER− premenopausal patients in situ to postmenopausal patients ([Figure 1](#f1-ott-10-1207){ref-type="fig"}). The expression of TLR-4 was found to be significantly associated with clinical parameters such as ER− pre- or postmenopausal age.

Interaction between TLR-4 polymorphism (*rs2770150*, *rs10759931*, *rs10759932*, and *rs4986790*) and breast cancer risk in the study populations
-------------------------------------------------------------------------------------------------------------------------------------------------

DNA samples obtained from the blood of 127 breast cancer patients and 117 healthy controls were included in this study. Distribution of TLR-4 SNPs genotype and allele frequencies in breast cancer cases and control population are given in [Table 2](#t2-ott-10-1207){ref-type="table"}. Four TLR-4 SNPs (*rs2770150* T/C, *rs10759931* A/G, *rs10759932* T/C, and *rs4986790* A/G) were genotyped and tested for the Hardy--Weinberg equilibrium. The distribution of alleles and genotypes and the association analysis are reported in [Table 2](#t2-ott-10-1207){ref-type="table"}. The data for three TLR-4 SNPs, *rs2770150*, *rs10759932*, and *rs4986790*, located in the promoter, did not present any correlation with breast cancer in the Saudi population ([Table 2](#t2-ott-10-1207){ref-type="table"}). However, the frequencies of *rs10759931* SNP (Asp299Gly) in breast cancer cases were significantly different from the healthy controls. The G allele was found to be significantly higher in frequency among the patients (36%) compared to the control group (27%) ([Table 2](#t2-ott-10-1207){ref-type="table"}). These data suggested that TLR-4 Asp299Gly SNP is strongly associated with increased susceptibility to breast cancer in the Saudi Arabian population.

Link between pre- and postmenopause status and the genotype frequencies of TLR-4 gene polymorphism in breast cancer patients
----------------------------------------------------------------------------------------------------------------------------

The analysis of the TLR-4 genotype distribution after correlation with age indicated that the median age of onset of breast cancer patients included in the study was 48 years. To investigate the association of TLR-4 SNPs with a younger age at diagnosis of breast cancer, we classified the patients as aged ≤48 or \>48 years. The genotype distribution for the individual SNP along with the statistical analysis is given in [Tables 3](#t3-ott-10-1207){ref-type="table"} and [4](#t4-ott-10-1207){ref-type="table"}. Interestingly, patients over 48 years of age showed higher numbers of the C allele of SNP rs2770150 than healthy subjects (43% versus 28%, respectively) (OR 1.985; 95% CI 1.177--3.346 and *P*=0.00956). The prevalence of the homozygous CC of the same SNP was also significantly increased in the patient group compared to the control group (24% versus 2%, respectively) ([Table 4](#t4-ott-10-1207){ref-type="table"}). However, we did not find any association between this SNP and the subpopulation of patients \<48 years of age ([Table 3](#t3-ott-10-1207){ref-type="table"}). Additionally, no significant difference in the distribution of genotypes between patients and healthy controls for both subpopulations was observed (*P*\>0.05) for the other three SNPs (*rs10759931*, *rs10759932*, and *rs4986790*; [Tables 3](#t3-ott-10-1207){ref-type="table"} and [4](#t4-ott-10-1207){ref-type="table"}).

Association between the genotype frequencies of TLR-4 gene polymorphism and ER status
-------------------------------------------------------------------------------------

We next wanted to evaluate the association of breast cancer risk with the individual SNPs based on the patient's ER status. The genotype distributions in the ER+ and the ER− breast cancer patient groups were compared with those of the ER+ and ER− control subjects, respectively ([Tables 5](#t5-ott-10-1207){ref-type="table"} and [6](#t6-ott-10-1207){ref-type="table"}). Interestingly, in the ER− group, the AA genotype of SNP *rs4986790* presented a frequency that was significantly higher in the patients than in the controls (98% versus 88%, respectively). Similarly, the genotype AG was significantly less frequent in the cases compared to the controls (2% versus 12%, respectively) (OR 0.16; 95% CI 0.020--1.257 and *P*=0.04860) ([Table 5](#t5-ott-10-1207){ref-type="table"}). However, this SNP was not associated with breast cancer in the ER+ group ([Table 6](#t6-ott-10-1207){ref-type="table"}). For SNPs *rs2770150*, *rs10759931*, and *rs10759932*, no significant difference in the distribution of genotypes between affected and non-affected ER+ and ER− status was observed (*P*\>0.05) ([Tables 5](#t5-ott-10-1207){ref-type="table"} and [6](#t6-ott-10-1207){ref-type="table"}).

Discussion
==========

TLR-4 activation has been previously shown to promote tumor progression and chemoresistance in breast cancer,[@b40-ott-10-1207],[@b41-ott-10-1207] whereas impairment of the TLR-4 signaling pathway can reduce breast cancer growth and prolong survival.[@b9-ott-10-1207] Our hypothesis is that TLR-4 plays an important role in activating innate immune system and that dysregulation of this receptor compromises the immune surveillance leading to breast cancer progression and metastasis. Using a Saudi population, we demonstrated that TLR-4 is overexpressed in ER−, postmenopausal breast cancer patients compared to normal controls. Thus, an increase in TLR-4 could be seen as a biological indicator of potential cancer in ER−, postmenopausal patients. Interestingly, the presence of a higher level of TLR-4 protein in breast cancer tissue supports previous studies reporting an overexpression of TLR-4 in various types of cancers, including gastric cancer,[@b42-ott-10-1207] breast cancer,[@b40-ott-10-1207],[@b41-ott-10-1207],[@b43-ott-10-1207] colon cancer,[@b38-ott-10-1207],[@b43-ott-10-1207] and ovarian cancer.[@b44-ott-10-1207] Higher TLR-4 expression was also shown to be significantly associated with invasive ductal carcinoma, one of the most common types of breast cancer.[@b45-ott-10-1207] Evidence has demonstrated that TLR-4 activation promotes tumor cell adhesion and metastasis.[@b46-ott-10-1207],[@b47-ott-10-1207] Injection of 4T1 tumor cells into TLR-4−/− mice leads to increased tumor volume and lung metastasis.[@b9-ott-10-1207] In agreement with these studies, we suggest that high activation of TLR-4 in breast cancerous tissues may promote tumor growth and resistance to apoptosis.

Genetic alterations in the TLR pathway are also known to be associated with an increased risk of developing breast cancer.[@b48-ott-10-1207] This is the first study investigating the role of several common TLR-4 polymorphisms in susceptibility to breast cancer in Saudi Arabia. We identified that the TLR-4 polymorphism *rs10759931* could be a risk factor for this disease in the Saudi Arabian population. This polymorphism affects the population regardless of ER status or age group. In contrast, the TLR-4 polymorphism *rs2770150* is correlated with breast cancer in patients 48 years and older, which is in agreement with the decreased levels of female sex hormones during the postmenopausal period. However, Marino[@b49-ott-10-1207] has linked the crucial role of estrogen and progesterone in protecting against colon cancer particularly in women patients.[@b49-ott-10-1207]--[@b52-ott-10-1207] Our previous study showed that TLR-4 rs2770150 is associated with colon cancer in postmenopausal Saudi women.[@b38-ott-10-1207] The *TLR-4* polymorphism *rs4986790* is associated with this malignancy in the ER− patient groups. These two SNPs were shown to be strongly associated with prostate cancer[@b53-ott-10-1207] and gastric cancer[@b54-ott-10-1207] in other studies and in other populations. TLR-4 *rs4986790* is the most common polymorphism, which causes an amino acid exchange (aspartate to glycine) at position 299 (Asp200Gly) located within the extracellular domain of the receptor. This polymorphism causes a significant local conformational change at the D299G site,[@b55-ott-10-1207] which may abolish ligand binding, and consequently, impair the TLR-4 signaling response to LPS.[@b56-ott-10-1207] This polymorphism was also shown to be associated with an increased risk of breast cancer.[@b33-ott-10-1207] Recently, we have demonstrated that these same TLR-4 SNPs were associated with TLR-4 expression and colon cancer susceptibility in Saudi patients.[@b38-ott-10-1207] Because TLR-4 plays an active role in the innate immune system, the loss of function of this protein may lead to a depressed immune response, thus promoting cancer development.

In conclusion, our study shows for the first time that TLR-4 polymorphism *rs10759931* is strongly associated with risk of breast cancer in the Saudi population. Our data suggest that genetic variation in TLR-4 may influence the development of this disease. We believe that our study provides support for a better understanding of the implication of TLR-4 polymorphism in breast tumorigenesis and for its eventual use as a cancer biomarker.

Supplementary material
======================

###### 

Characteristics of selected TLR-4 polymorphisms

  SNP          Chr/position      Nucleotide change   Region
  ------------ ----------------- ------------------- -------------
  rs2770150    Chr 9/117700861   −3612T \> C         5′ upstream
  rs10759931   Chr 9/117701869   −2604G \> A         Promoter
  rs10759932   Chr 9/120465144   −1607T \> C         Promoter
  rs4986790    Chr 9/117713024   8552A \> G          Exon
  Asp299Gly                                          

**Abbreviations:** TLR-4, Toll-like receptor 4; SNP, single-nucleotide polymorphism; Chr, chromosome.
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![Immunohistochemical determination of TLR-4 protein expression in normal and breast cancer tissues. (**A**) Representative sections (×200) of positive immunostaining of TLR-4 protein expression in normal breast tissues (a and b) and ER− breast cancer tissues (c and d). The staining of samples from ER− premenopausal patients is illustrated in (a and c) and from ER− postmenopausal patients in (b and d). Tissues were immunostained using specific TLR-4 antibodies. (**B**) TLR-4 positive staining was estimated as follows: 0 point, no positive staining; 1 point, \<20% positive staining; 2 points, 21%--50% positive staining; 3 points, 51%--75% positive staining; and 4 points, \>75% positive staining.\
**Abbreviations:** TLR-4, Toll-like receptor 4; ER, estrogen receptor.](ott-10-1207Fig1){#f1-ott-10-1207}

###### 

Clinical characteristics of study subjects

  Variable               Characteristic                                     Patients   Controls
  ---------------------- -------------------------------------------------- ---------- ----------
  Total                  --                                                 127        116
  Age (years)            \<48                                               45         62
  (median age, 48±8.2)   \>48[\*](#tfn1-ott-10-1207){ref-type="table-fn"}   82         54
  ER status              ER+                                                76         --
                         ER−                                                49         --
  PR status              PR+                                                71         --
                         PR−                                                55         --
  HER status             HER+                                               49         --
                         HER−                                               78         --

**Note:**

*χ*^2^ analysis showed significant difference between cases and controls.

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor; HER, human epidermal growth factor receptor.

###### 

Frequencies of TLR-4 gene polymorphism in breast cancer

  Polymorphism   Patients     Control      OR      CI              *χ*^2^   *P*-value
  -------------- ------------ ------------ ------- --------------- -------- -----------------------------------------------------
  rs2770150                                                                 
  T              154 (0.62)   87 (0.70)    Ref                              
  C              96 (0.38)    37 (0.30)    1.466   0.924--2.325    2.65     0.10347
  TT             53 (0.42)    32 (0.52)    Ref                              
  TC             48 (0.38)    23 (0.37)    1.260   0.649--2.445    0.47     0.49409
  CC             24 (0.19)    7 (0.11)     2.070   0.801--5.349    2.31     0.12850
  TC + CC        72 (0.58)    30 (0.48)    1.449   0.786--2.671    1.42     0.23360
  rs10759931                                                                
  G              91 (0.36)    62 (0.27)    Ref                              
  A              161 (0.64)   170 (0.73)   0.645   0.438--0.951    4.92     0.02650[\*](#tfn3-ott-10-1207){ref-type="table-fn"}
  AA             13 (0.10)    8 (0.07)     Ref                              
  GA             65 (0.52)    46 (0.40)    0.870   0.334--2.267    0.08     0.77488
  GG             48 (0.38)    62 (0.53)    0.476   0.183--1.242    2.37     0.12407
  GA + GG        113 (0.90)   108 (0.93)   0.644   0.257--1.615    0.89     0.34496
  rs10759932                                                                
  T              39 (0.15)    43 (0.19)    Ref                              
  C              213 (0.85)   179 (0.81)   1.312   0.814--2.113    1.25     0.26348
  CC             4 (0.03)     6 (0.05)     Ref                              
  TC             31 (0.25)    31 (0.28)    1.500   0.385--5.842    0.34     0.55712
  TT             91 (0.72)    74 (0.67)    1.845   0.502--6.781    0.87     0.35034
  TC + TT        122 (0.97)   105 (0.95)   1.743   0.479--6.343    0.73     0.39396
  rs4986790                                                                 
  A              238 (0.97)   216 (0.94)   Ref                              
  G              8 (0.03)     14 (0.06)    0.519   0.213--1.260    2.17     0.14099
  AA             115 (0.93)   101 (0.88)   Ref                              
  AG             8 (0.07)     14 (0.12)    0.502   0.202--1.245    2.28     0.13127
  GG             0 (0.00)     0 (0.00)     0.879   0.017--44.691   --       1
  AG + GG        8 (0.07)     14 (0.12)    0.502   0.202--1.245    2.28     0.13127

**Note:**

Statistically significant (*P*\<0.05).

**Abbreviations:** TLR-4, Toll-like receptor 4; OR, odds ratio; CI, confidence interval; Ref, reference.

###### 

Genotype frequencies of TLR-4 in breast cancer patients aged \<48 years versus control

  Polymorphism   Patients    Control      OR      CI              *χ*^2^   *P*-value
  -------------- ----------- ------------ ------- --------------- -------- -----------
  rs2770150                                                                
  TT             22 (0.51)   32 (0.52)    Ref                              
  TC             17 (0.40)   23 (0.37)    1.075   0.469--2.464    0.03     0.86410
  CC             4 (0.09)    7 (0.11)     0.831   0.217--3.184    0.07     0.78709
  TC + CC        21 (0.49)   30 (0.48)    1.018   0.468--2.217    0.00     0.96380
  T              61 (0.71)   87 (0.70)    Ref                              
  C              25 (0.29)   37 (0.30)    0.964   0.527--1.763    0.01     0.90438
  rs10759931                                                               
  AA             6 (0.14)    5 (0.08)     Ref                              
  GA             21 (0.48)   25 (0.40)    0.700   0.187--2.623    0.28     0.59564
  GG             17 (0.39)   32 (0.52)    0.443   0.118--1.665    1.50     0.22104
  GA + GG        38 (0.86)   57 (0.92)    0.556   0.158--1.950    0.86     0.35400
  G              33 (0.38)   35 (0.28)    Ref                              
  A              55 (0.63)   89 (0.72)    0.655   0.366--1.173    2.03     0.15402
  rs10759932                                                               
  CC             0 (0.00)    4 (0.07)     Ref                              
  TC             11 (0.25)   13 (0.22)    7.667   0.372--158      3.02     0.08226
  TT             33 (0.75)   41 (0.71)    7.265   0.378--139.78   3.09     0.07868
  TC + TT        44 (1.00)   54 (0.93)    7.349   0.38--140.18    3.16     0.07554
  T              11 (0.13)   21 (0.18)    Ref                              
  C              77 (0.88)   95 (0.82)    1.547   0.703--3.406    1.19     0.27574
  rs4986790                                                                
  AA             41 (0.93)   53 (0.85)    Ref                              
  AG             3 (0.07)    9 (0.15)     0.431   0.110--1.694    1.52     0.21775
  GG             0 (0.00)    0 (0.00)     1.289   0.025--66.34    --       1
  AG + GG        3 (0.07)    9 (0.15)     0.431   0.110--1.694    1.52     0.21775
  A              85 (0.97)   115 (0.93)   Ref                              
  G              3 (0.03)    9 (0.07)     0.451   0.119--1.716    1.43     0.36680

**Abbreviations:** TLR-4, Toll-like receptor 4; OR, odds ratio; CI, confidence interval; Ref, reference.

###### 

Genotype frequencies of TLR-4 in breast cancer patients aged \>48 years versus control

  Polymorphism   Patients     Control      OR       CI              *χ*^2^   *P*-value
  -------------- ------------ ------------ -------- --------------- -------- -----------------------------------------------------
  rs2770150                                                                  
  TT             31 (0.38)    25 (0.46)    Ref                               
  TC             31 (0.38)    28 (0.52)    0.893    0.429--1.860    0.09     0.76214
  CC             20 (0.24)    1 (0.02)     16.129   2.022--128.63   10.86    0.00098[\*](#tfn6-ott-10-1207){ref-type="table-fn"}
  TC + CC        51 (0.62)    29 (0.54)    1.418    0.707--2.847    0.97     0.32487
  T              93 (0.57)    78 (0.72)    Ref                               
  C              71 (0.43)    30 (0.28)    1.985    1.177--3.346    6.71     0.00956[\*](#tfn6-ott-10-1207){ref-type="table-fn"}
  rs10759931                                                                 
  AA             7 (0.09)     3 (0.06)     Ref                               
  GA             44 (0.54)    21 (0.39)    0.898    0.211--3.824    0.02     0.88421
  GG             31 (0.38)    30 (0.56)    0.443    0.105--1.874    1.27     0.25966
  GA + GG        75 (0.91)    51 (0.94)    0.630    0.156--2.552    0.42     0.51459
  G              58 (0.35)    27 (0.25)    Ref                               
  A              106 (0.65)   81 (0.75)    0.609    0.355--1.046    3.26     0.07113
  rs10759932                                                                 
  CC             4 (0.05)     2 (0.04)     Ref                               
  TC             20 (0.24)    18 (0.34)    0.556    0.091--3.405    0.41     0.52111
  TT             58 (0.71)    33 (0.62)    0.879    0.153--5.059    0.02     0.88489
  TC + TT        78 (0.95)    51 (0.96)    0.765    0.135--4.329    0.09     0.76106
  T              28 (0.17)    22 (0.21)    Ref                               
  C              136 (0.83)   84 (0.79)    1.272    0.684--2.367    0.58     0.44696
  rs4986790                                                                  
  AA             74 (0.94)    48 (0.91)    Ref                               
  AG             5 (0.06)     5 (0.09)     0.649    0.178--2.360    0.44     0.50871
  GG             0 (0.00)     0 (0.00)     0.651    0.013--33.359   --       1
  AG + GG        5 (0.06)     5 (0.09)     0.649    0.178--2.360    0.44     0.50871
  A              153 (0.97)   101 (0.95)   Ref                               
  G              5 (0.03)     5 (0.05)     0.660    0.186--2.338    0.42     0.52871

**Note:**

Statistically significant (*P*\<0.05).

**Abbreviations:** TLR-4, Toll-like receptor 4; OR, odds ratio; CI, confidence interval; Ref, reference.

###### 

Genotype frequencies of TLR-4 in ER− breast cancer patients versus control

  Polymorphism   Patients    Control      OR      CI              *χ*^2^   *P*-value
  -------------- ----------- ------------ ------- --------------- -------- -----------------------------------------------------
  rs2770150                                                                
  TT             23 (0.47)   32 (0.52)    Ref                              
  TC             18 (0.37)   23 (0.37)    1.089   0.481--2.465    0.04     0.83819
  CC             8 (0.16)    7 (0.11)     1.590   0.505--5.008    0.63     0.42612
  TC + CC        26 (0.53)   30 (0.48)    1.206   0.569--2.553    0.24     0.62478
  T              64 (0.65)   87 (0.70)    Ref                              
  C              34 (0.35)   37 (0.30)    1.249   0.709--2.201    0.59     0.44120
  rs10759931                                                               
  AA             5 (0.10)    8 (0.07)     Ref                              
  GA             26 (0.53)   46 (0.40)    0.904   0.268--3.052    0.03     0.87128
  GG             18 (0.37)   62 (0.53)    0.465   0.135--1.596    1.53     0.21603
  GA + GG        44 (0.90)   108 (0.93)   0.652   0.202--2.102    0.52     0.47117
  G              36 (0.37)   62 (0.27)    Ref                              
  A              62 (0.63)   170 (0.73)   0.628   0.380--1.039    3.31     0.06899
  rs10759932                                                               
  CC             1 (0.02)    6 (0.05)     Ref                              
  TC             12 (0.24)   31 (0.28)    2.323   0.252--21.372   0.58     0.44610
  TT             36 (0.73)   74 (0.67)    2.919   0.339--25.162   1.04     0.30897
  TC + TT        48 (0.98)   105 (0.95)   2.743   0.321--23.415   0.92     0.33752
  T              14 (0.14)   43 (0.19)    Ref                              
  C              84 (0.86)   179 (0.81)   1.441   0.748--2.779    1.20     0.27328
  rs4986790                                                                
  AA             45 (0.98)   101 (0.88)   Ref                              
  AG             1 (0.02)    14 (0.12)    0.160   0.020--1.257    3.89     0.04860[\*](#tfn8-ott-10-1207){ref-type="table-fn"}
  GG             0 (0.00)    0 (0.00)     2.231   0.044--114.18   --       1
  AG + GG        1 (0.02)    14 (0.12)    0.160   0.020--1.257    3.89     0.04860[\*](#tfn8-ott-10-1207){ref-type="table-fn"}
  A              91 (0.99)   216 (0.94)   Ref                              
  G              1 (0.01)    14 (0.06)    0.170   0.022--1.308    3.70     0.07686

**Note:**

Statistically significant (*P*\<0.05).

**Abbreviations:** TLR-4, Toll-like receptor 4; ER, estrogen receptor; OR, odds ratio; CI, confidence interval; Ref, reference.

###### 

Genotype frequencies of TLR-4 in ER+ breast cancer patients versus control

  Polymorphism   Patients     Control      OR      CI              *χ*^2^   *P*-value
  -------------- ------------ ------------ ------- --------------- -------- -----------
  rs2770150                                                                 
  TT             30 (0.41)    32 (0.52)    Ref                              
  TC             29 (0.39)    23 (0.37)    1.345   0.642--2.819    0.62     0.43208
  CC             15 (0.20)    7 (0.11)     2.286   0.819--6.378    2.56     0.10973
  TC + CC        44 (0.59)    30 (0.48)    1.564   0.792--3.090    1.67     0.19662
  T              89 (0.60)    87 (0.70)    Ref                              
  C              59 (0.40)    37 (0.30)    1.559   0.940--2.586    2.97     0.08483
  rs10759931                                                                
  AA             8 (0.11)     8 (0.07)     Ref                              
  GA             38 (0.51)    46 (0.40)    0.826   0.283--2.408    0.12     0.72614
  GG             29 (0.39)    62 (0.53)    0.468   0.160--1.370    1.98     0.15965
  GA + GG        67 (0.89)    108 (0.93)   0.620   0.222--1.731    0.84     0.35839
  G              54 (0.36)    62 (0.27)    Ref                              
  A              96 (0.64)    170 (0.73)   0.648   0.417--1.009    3.71     0.05419
  rs10759932                                                                
  CC             3 (0.04)     6 (0.05)     Ref                              
  TC             18 (0.24)    31 (0.28)    1.161   0.258--5.219    0.04     0.84527
  TT             54 (0.72)    74 (0.67)    1.459   0.349--6.096    0.27     0.60244
  TC + TT        72 (0.96)    105 (0.95)   1.371   0.332--5.662    0.19     0.66126
  T              24 (0.16)    43 (0.19)    Ref                              
  C              126 (0.84)   179 (0.81)   1.261   0.728--2.184    0.69     0.40678
  rs4986790                                                                 
  AA             68 (0.91)    101 (0.88)   Ref                              
  AG             7 (0.09)     14 (0.12)    0.743   0.285--1.936    0.37     0.54160
  GG             0 (0.00)     0 (0.00)     1.482   0.029--75.574   --       1
  AG + GG        7 (0.09)     14 (0.12)    0.743   0.285--1.936    0.37     0.54160
  A              143 (0.95)   216 (0.94)   Ref                              
  G              7 (0.05)     14 (0.06)    0.755   0.298--1.917    0.35     0.55367

**Abbreviations:** TLR-4, Toll-like receptor 4; ER, estrogen receptor; OR, odds ratio; CI, confidence interval; Ref, reference.
